Abdul El-Sayed, the newly elected senator from Michigan, has appointed Diana Abdelall, a former lobbyist for Big Pharma, to lead his Senate transition. This decision has raised eyebrows, particularly given El-Sayed's campaign against the pharmaceutical industry.
1. Appointment of Diana Abdelall:
• El-Sayed has selected Abdelall, who previously worked for pharmaceutical companies like Bayer.
• She has a history of lobbying for drug companies concerning health policy and Medicare issues.
2. Campaign Contradictions:
• El-Sayed campaigned as a strong opponent of Big Pharma, advocating for "money out of politics" and "Medicare for All".
• He criticized his Republican opponent for alleged ties to the pharmaceutical industry, which were later proven false.
3. Reception of the Appointment:
• Supporters of El-Sayed view Abdelall’s experience positively, suggesting she will help him build a competent Senate team.
• Critics within his liberal base question the choice, especially as he has positioned himself against the practices of big drug manufacturers.
4. Controversial Statements and Views:
• Abdelall has previously made controversial remarks linking "Zionists" to control over American politics, a stance that aligns with El-Sayed’s own criticisms of Israel.
• El-Sayed's past statements have drawn attention for equating Israel with Iran and disputing Israel's status as a U.S. ally.
El-Sayed's decision to appoint a former Big Pharma lobbyist as his Senate transition director has sparked significant discussion and criticism among his supporters and opponents. The implications of this appointment may affect his plans and relationships within the Senate, particularly in regard to healthcare reform and his stance on Israel.
No comments:
Post a Comment